Terazosin

Terazosin capsules treat symptomatic benign prostatic hyperplasia and hypertension, alone or with other antihypertensives. Relief of urinary symptoms does not establish prevention of BPH surgery, acute obstruction or other long-term complications, whose effects are undetermined in the label.

This profile covers selected current U.S. immediate-release capsules. BPH evaluation should exclude prostate cancer or other causes; coexistence is possible. Pediatric / off-label, compounded, other-manufacturer identification and disease-specific first-line-treatment claims are outside the reviewed scope.

Start 1 mg at bedtime; slowly titrate to BP response. Usual 1–5 mg once daily; some benefit up to 20 mg / day. Above 20 mg does not appear to add BP effect; above 40 mg was not studied, which is not a recommended 40 mg cap. Monitor end-of-interval BP;2–3 hour post-dose measurements can assess excessive peak response. If effect wanes by 24 hours, the prescriber may consider adjusted dose or divided twice-daily treatment; do not independently shorten intervals.

After interruption for several days or longer, restart the initial dosing regimen rather than the previous higher dose. Adding antihypertensives, particularly verapamil, may require dose reduction / retitration of either treatment. PDE5-inhibitor co-use can cause hypotension. No fixed titration-day schedule or missed-single-dose double-up rule is supplied; consult the prescribing plan.

Known hypersensitivity to terazosin hydrochloride is the selected formal contraindication. Severe orthostatic risk requires careful selection and dosing; it is not inaccurately substituted for a different formal contraindication list.

Selected labels have no boxed warning. The prominent first-dose syncope warning and mandatory 1 mg start still apply.

Reports include dizziness, weakness / fatigue, somnolence, headache, nasal congestion, nausea, edema, palpitations, blurred vision and sexual-function effects. Serious events include syncope, priapism and rare hypersensitivity / anaphylaxis; postmarketing atrial fibrillation and thrombocytopenia are reported. BPH and hypertension trial frequencies differ and are not pooled into a universal risk estimate.

Other BP medicines, especially verapamil, require caution and possible dose reduction / retitration. PDE5 inhibitors have caused hypotension with terazosin. Review timing, BP and symptoms with the clinician; no universal separation interval or combination dose is supplied.

Selected labels describe co-use with many medicines without unexpected interactions, but some observations were not formal interaction studies. Review OTC decongestants, sedatives, alcohol and all new prescriptions for BP or impairment concerns rather than claim that the historical drug list proves universal compatibility.

Selected labels lack adequate controlled pregnancy studies and report adverse developmental findings at high animal exposure; use is not recommended unless benefit justifies maternal / fetal risk. HistoricalCategoryC wording is not a current quantitative risk estimate. Human milk transfer is unknown and nursing use needs caution.

Pediatric safety / effectiveness is undetermined; no dose is supplied. Older subjects showed reduced clearance / longer half-life in label PK studies. Review falls, orthostatic symptoms, other BP medicines and organ status; no age-only higher-dose allowance is inferred.

Renal impairment had no significant effect on elimination in selected label data; compensatory dosing for the approximately 10% removal during hemodialysis does not appear necessary. No numeric hepatic adjustment table or advanced-organ dosing algorithm is supplied. Individual BP / tolerance and the initial / restart regimen remain essential.

Terazosin blocks alpha-1 adrenoceptors. Relaxation of bladder-neck / prostatic smooth muscle improves urinary flow and symptoms; vascular effects reduce BP. The selected label’s clinical response findings do not establish prevention of all BPH complications.

Capsules are nearly completely absorbed; meals minimally affect extent but delay peak. Plasma peaks around 1 hour, with half-life about 12 hours and somewhat longer in older subjects. Protein binding is 90–94%; parent plus metabolites leave through urine and feces. Minimal first-pass metabolism and kidney PK findings do not create a universal hepatic-safe claim.

Before BPH treatment assess other urinary pathology / prostate cancer. Follow urinary symptoms / flow and BP, especially standing symptoms after initiation / escalation / restart. For hypertension assess trough BP and excessive peak effect as above. Review fall risk, medicines and need for dose changes. Trial hemodilution-related lab changes do not establish a universal CBC-monitoring schedule or a guaranteed unchanged PSA for every patient.

Take the initial 1 mg at bedtime. Avoid driving / hazardous tasks for 12 hours after the first dose, an increase or resumption after interruption; drowsiness can require additional caution. Rise carefully; sit or lie down if dizzy and report bothersome symptoms. Seek immediate help for syncope or prolonged painful erection. Tell eye surgeons about any past use. Consult before restarting after several days; do not double an uncertain dose.

Seek emergency / Poison Control help for overdose or severe hypotension. Clinical care supports BP / heart rate and renal function; supine positioning while awaiting care may help if safe. Volume / vasopressor treatment belongs to medical care. High protein binding makes dialysis unlikely to help substantially.

Product

Remedy Repack terazosin 1 mg capsule

Route

Oral prescription capsule

Appearance

Iron-gray opaque; TL 383 black print

Example package

30-capsule blister · NDC 70518-0342-00

The reviewed label regimen discusses 1 / 2 / 5 / 10 mg strengths. Actual selected packages reviewed here are 1 mg above and 5 mg (orange opaque TL 385),30-capsule blister NDC 70518-0317-00. Other strengths / manufacturers require the actual label for identification; strength reflects terazosin supplied as hydrochloride.

Both selected repackaged products:20–25°C, protect from light / moisture and dispense in a tight light-resistant container. Follow the actual dispensing expiry. No reviewed compounded-liquid, crushing or feeding-tube stability instructions are supplied.